Supportive Care in Cancer

, Volume 22, Issue 2, pp 513–518

A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

  • Sina Vatandoust
  • Rohit Joshi
  • Kenneth B. Pittman
  • Adrian Esterman
  • Vy Broadbridge
  • Jacqueline Adams
  • Nimit Singhal
  • Susan Yeend
  • Timothy Jay Price
Original Article

DOI: 10.1007/s00520-013-2004-3

Cite this article as:
Vatandoust, S., Joshi, R., Pittman, K.B. et al. Support Care Cancer (2014) 22: 513. doi:10.1007/s00520-013-2004-3

Abstract

Background

Prolonged neurotoxicity after systemic chemotherapy has the potential to impact on quality of life. We explored the frequency of persistent peripheral neuropathy in patients who received oxaliplatin for colorectal cancer at two local centres.

Patients and methods

Questionnaires were sent to patients who completed treatment with oxaliplatin for colorectal cancer at least 20 months prior to entering the study. Neuropathy questions were adapted from the FACT/GOG-Ntx (V.4) questionnaire.

Results

Of the 56 eligible patients, 27 returned the questionnaire. Twenty-five patients (93 %) experienced neuropathic symptoms during their treatment; 11 had grade-2, and two had grade-3 symptoms. At the time of completing the questionnaire, 17 patients (63.0 %; 95%CI 43.9–79.4 %) were still symptomatic with 12 patients (44.4 %; 95%CI 26.8–63.3) having grade-2 or grade-3 symptoms and three patients (11.1 %; 95%CI 2.9–27.3) having grade-3 neuropathic symptoms. Participants who received more than 900 mg/m2 oxaliplatin had a significantly higher risk of persistent grade-2 or grade-3 neuropathy (p = 0.031, RR = 8.3 95%CI = 1.2–57.4). There was a trend toward increased risk of persistent neuropathy of any grade among participants with a history of regular alcohol use (p = 0.051; RR = 1.7 95%CI 1.0–2.8).

Conclusion

Persistent oxaliplatin-induced neuropathy is not as uncommon as previously suggested, and the rate of grade-2 and grade-3 symptoms could be considerably higher than previous reports.

Keywords

Oxaliplatin Neurotoxicity syndromes Colorectal neoplasms Antineoplastic agents Colonic neoplasms Rectal neoplasms Antineoplastic combined chemotherapy protocols 

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Sina Vatandoust
    • 1
    • 6
  • Rohit Joshi
    • 1
  • Kenneth B. Pittman
    • 3
  • Adrian Esterman
    • 4
  • Vy Broadbridge
    • 3
  • Jacqueline Adams
    • 1
  • Nimit Singhal
    • 1
  • Susan Yeend
    • 3
  • Timothy Jay Price
    • 5
  1. 1.Department of Medical OncologyLyellMcEwin HospitalAdelaideAustralia
  2. 2.Department of Medical OncologyLyell McEwin HospitalAdelaideAustralia
  3. 3.Department of Medical OncologyThe Queen Elizabeth HospitalAdelaideAustralia
  4. 4.Sansom Institute of Health Service Research and School of Nursing and MidwiferyThe University of South AustraliaAdelaideAustralia
  5. 5.The Queen Elizabeth Hospital and University of AdelaideAdelaideAustralia
  6. 6.Department of Medical OncologyFlinders Centre for Innovation in CancerAdelaideAustralia

Personalised recommendations